肝硬化肾损伤的发病机制与诊治进展

刘清清; 杨婧; 胡绍山; 李苹菊; 金秋; 马红琳

doi:10.3969/j.issn.1001-5256.2023.06.032

肝硬化肾损伤的发病机制与诊治进展

DOI: 10.3969/j.issn.1001-5256.2023.06.032

昆明医科大学第二附属医院消化内科，昆明 650106

基金项目:

昆明医科大学第二附属医院院内临床项目 (ynllT2021012)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：刘清清负责文章设计并撰写论文；胡绍山、李苹菊、马红琳、金秋参与查阅并整理分析文献；杨婧负责指导撰写修改论文。

详细信息

通信作者:
杨婧，yangjing_dl@163.com (ORCID：0000-0002-3526-7552)

计量
- 文章访问数: 323
- HTML全文浏览量: 58
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-06
- 录用日期: 2022-11-07
- 出版日期: 2023-06-20

Advances in the pathogenesis, diagnosis, and treatment of renal injury in liver cirrhosis

Department of Gastroenterology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, China

Research funding:

In Hospital Clinical Project of the Second Affiliated Hospital of Kunming Medical University (ynllT2021012)

More Information

Corresponding author: YANG Jing, yangjing_dl@163.com (ORCID: 0000-0002-3526-7552)

摘要

摘要: 肝硬化失代偿期患者常因严重的肝功能不全导致扩血管物质灭活减少、血流动力学紊乱、体内免疫系统紊乱、感染等因素引起肾功能的下降，若不及时干预则会由早期的肾前性损伤逐步发展至晚期的肾衰竭，患者存活率低、治疗难度大。随着肾损伤的分类和诊断标准逐渐明确，以及越来越多的肾损伤标志物得以发现，早期诊断及定位肾损伤的阶段对改善患者预后非常重要。本文分析了近年来肝硬化患者肾损伤的发病机制、诊断标准及治疗方面的新进展。以期为临床肝硬化肾损伤患者的诊治提供帮助。
- 肝硬化 /
- 肾损伤 /
- 诊断 /
- 治疗学
Abstract: Patients with decompensated cirrhosis often have a reduction in renal function due to severe hepatic insufficiency which results in reduced inactivation of vasodilators, hemodynamic disorders, immune disorders, and infections, and without timely intervention, patients may gradually develop from early prerenal injury to late renal failure. Patients tend to have a low survival rate and great difficulties in treatment. With the gradual clarification of the classification and diagnostic criteria for kidney injury and the discovery of an increasing number of markers for kidney injury, early diagnosis and localization of kidney injury are of great importance for improving the prognosis of patients. This article analyzes the new advances in the pathogenesis, diagnostic criteria, and treatment of renal injury in cirrhotic patients in recent years, so as to provide help for the clinical diagnosis and treatment of cirrhotic patients with renal injury.
- Liver Cirrhosis /
- Kidney Injury /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(41)

[1]	ANGELI P, GARCIA-TSAO G, NADIM MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document[J]. J Hepatol, 2019, 71(4): 811-822. DOI: 10.1016/j.jhep.2019.07.002.
[2]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[3]	XIAO AX, WU XJ. Research progress of non -vasodilation mechanism of liver cirrhosis complicated with acute kidney injury[J]. Systems Medicine, 2021, 6(22): 194-198. DOI: 10.19368/j.cnki.2096-1782.2021.22.194. 肖安喜, 吴雄健. 肝硬化并发急性肾损伤的非血管舒张机制的研究进展[J]. 系统医学, 2021, 6(22): 194-198. DOI: 10.19368/j.cnki.2096-1782.2021.22.194.
[4]	VAN SLAMBROUCK CM, SALEM F, MEEHAN SM, et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction[J]. Kidney Int, 2013, 84(1): 192-197. DOI: 10.1038/ki.2013.78.
[5]	KDIGO AKI. Kidney Disease Improving Global Outcomes. AKI Work Group: Clinical practice guideline for acute kidney injury[J]. Kidney Inter Suppl, 2012(2): 1-138.
[6]	ANGELI P, GINES P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Gut, 2015, 64(4): 531-537. DOI: 10.1136/gutjnl-2014-308874.
[7]	LEI L, LI LP, ZHANG H. Analysis of risk factors for the secondary acute kidney injury in patients with cirrhotic ascites[J]. Pract J Clin Med, 2018, 15(1): 7-10. DOI: 10.3969/j.issn.1672-6170.2018.01.003. 雷蕾, 李良平, 张虎. 肝硬化腹水继发急性肾损伤患者相关因素分析[J]. 实用医院临床杂志, 2018, 15(1): 7-10. DOI: 10.3969/j.issn.1672-6170.2018.01.003.
[8]	LU XW, YANG J. Analysis on the risk factors of cirrhosis combined with renal damage[J]. China Mod Doct, 2021, 59(19): 96-99. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202119033.htm 陆秀伟, 杨娟. 肝硬化合并肾损害的危险因素分析[J]. 中国现代医生, 2021, 59(19): 96-99. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202119033.htm
[9]	WANG WJ, SONG Q, DING HG. Clinical characteristics and risk factors of acute kidney injury in patients with liver cirrhosis[J]. Chin J Intern Med, 2018, 57(12): 912-916. DOI: 10.3760/cma.j.issn.0578-1426.2018.12.007. 王文娟, 宋琦, 丁惠国. 肝硬化患者急性肾损伤的临床特点及危险因素分析[J]. 中华内科杂志, 2018, 57(12): 912-916. DOI: 10.3760/cma.j.issn.0578-1426.2018.12.007.
[10]	LIU Y, HE X, TAIN ZY, et al. Clinical features and risk factors of acute kidney injury in patients with viral hepatitis B-induced liver cirrhosis[J]. J Pract Hepatol, 2021, 24(4): 524-527. DOI: 10.3969/j.issn.1672-5069.2021.04.018. 刘颖, 何显, 田志颖, 等. 乙型肝炎肝硬化并发急性肾损伤患者临床特点及其危险因素分析[J]. 实用肝脏病杂志, 2021, 24(4): 524-527. DOI: 10.3969/j.issn.1672-5069.2021.04.018.
[11]	HAN CM, HAN YF, WANG CH. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis[J]. J Pract Hepatol, 2021, 24(6): 883-886. DOI: 10.3969/j.issn.1672-5069.2021.06.029. 韩成美, 韩永峰, 王春华. 乙型肝炎肝硬化患者并发急性肾损伤危险因素分析[J]. 实用肝脏病杂志, 2021, 24(6): 883-886. DOI: 10.3969/j.issn.1672-5069.2021.06.029.
[12]	BELCHER JM, GARCIA-TSAO G, SANYAL AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis[J]. Hepatology, 2013, 57(2): 753-762. DOI: 10.1002/hep.25735.
[13]	PIANO S, ROSI S, MARESIO G, et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites[J]. J Hepatol, 2013, 59(3): 482-489. DOI: 10.1016/j.jhep.2013.03.039.
[14]	FAGUNDES C, BARRETO R, GUEVARA M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis[J]. J Hepatol, 2013, 59(3): 474-481. DOI: 10.1016/j.jhep.2013.04.036.
[15]	WONG F, O'LEARY JG, REDDY KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection[J]. Gastroenterology, 2013, 145(6): 1280-1288. e1. DOI: 10.1053/j.gastro.2013.08.051.
[16]	SIMONETTO DA, GINES P, KAMATH PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management[J]. BMJ, 2020, 370: m2687. DOI: 10.1136/bmj.m2687.
[17]	ZHANG M, PU L, XIONG HF, et al. Comparison of KDIGO and ICA criteria in diagnosing acute kidney injury in critically ill cirrhotic patients[J]. J Pract Hepatol, 2020, 23(3): 392-396. DOI: 10.3969/j.issn.1672-5069.2020.03.023. 张铭, 蒲琳, 熊号峰, 等. KDIGO和ICA标准诊断住ICU的肝硬化患者急性肾损伤效能研究[J]. 实用肝脏病杂志, 2020, 23(3): 392-396. DOI: 10.3969/j.issn.1672-5069.2020.03.023.
[18]	WAGENER G, JAN M, KIM M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery[J]. Anesthesiology, 2006, 105(3): 485-491. DOI: 10.1097/00000542-200609000-00011.
[19]	YUAN DC, GONG XZ, LIU JL, et al. Research progress of new biomarkers related to acute renal injury[J]. China Med Herald, 2022, 19(1): 44-47. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202201012.htm 原道川, 龚学忠, 刘建联, 等. 急性肾损伤相关新型生物标志物的研究进展[J]. 中国医药导报, 2022, 19(1): 44-47. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202201012.htm
[20]	KIM TH, SEO YS, KANG SH, et al. Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study[J]. Liver Int, 2020, 40(12): 3083-3092. DOI: 10.1111/liv.14631.
[21]	PIANO S, ROMANO A, DI PASCOLI M, et al. Why and how to measure renal function in patients with liver disease[J]. Liver Int, 2017, 37 Suppl 1: 116-122. DOI: 10.1111/liv.13305.
[22]	PARIKH CR, MANSOUR SG. Perspective on clinical application of biomarkers in AKI[J]. J Am Soc Nephrol, 2017, 28(6): 1677-1685. DOI: 10.1681/ASN.2016101127.
[23]	XU MM, CHEN Y. An analysis of urinary factors for predicting acute kidney injury in patients with liver cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2124-2129. DOI: 10.3969/j.issn.1001-5256.2018.10.013. 徐曼曼, 陈煜. 肝硬化合并急性肾损伤的尿液相关预测因素分析[J]. 临床肝胆病杂志, 2018, 34(10): 2124-2129. DOI: 10.3969/j.issn.1001-5256.2018.10.013.
[24]	WANG JJ, LI CT, ZHOU WZ. Urineretinol binding protein levels in patients with hepatitis B-induced decompensated liver cirrbosis as the index for acute kidney injury[J]. J Pract Hepatol, 2020, 23(1): 74-77. DOI: 10.3969/j.issn.1672-5069.2020.01.021. 王晶晶, 李春涛, 周卫真. 失代偿期乙型肝炎肝硬化患者尿液视黄醇结合蛋白水平及其临床意义探讨[J]. 实用肝脏病杂志, 2020, 23(1): 74-77. DOI: 10.3969/j.issn.1672-5069.2020.01.021.
[25]	DENG AH, CHEN ZM, XIA XC. Clinical significance of serum cystatin C in patients with liver cirrhosis secondary renal impairment[J]. Nei Mongol J Tradit Chin Med, 2012, 31(16): 82-83. DOI: 10.3969/j.issn.1006-0979.2012.16.096. 邓爱华, 陈志敏, 夏晓彩. 肝硬化继发肾功能损害患者检测血清胱抑素C的临床意义[J]. 内蒙古中医药, 2012, 31(16): 82-83. DOI: 10.3969/j.issn.1006-0979.2012.16.096.
[26]	ARORA V, MAIWALL R, RAJAN V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology, 2020, 71(2): 600-610. DOI: 10.1002/hep.30208.
[27]	JAMIL K, PAPPAS SC, DEVARAKONDA KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2[J]. J Exp Pharmacol, 2018, 10: 1-7. DOI: 10.2147/JEP.S146034.
[28]	XU MM, CHEN Y, LI S. Predictive value of urinary NGAL and KIM-1 for response of patients with hepatorenal syndrome to terlipressin combined with albumin infusion treatment[J]. J Pract Hepatol, 2019, 22(3): 385-388. DOI: 10.3969/j.issn.1672-5069.2019.03.019. 徐曼曼, 陈煜, 李爽. 特利加压素联合白蛋白输注治疗肝肾综合征患者疗效及尿NGAL和KIM-1对疗效的预测价值[J]. 实用肝脏病杂志, 2019, 22(3): 385-388. DOI: 10.3969/j.issn.1672-5069.2019.03.019.
[29]	TANOUE A, ITO S, HONDA K, et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions[J]. J Clin Invest, 2004, 113(2): 302-309. DOI: 10.1172/JCI19656.
[30]	WONG F, PAPPAS SC, BOYER TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017, 15(2): 266-272. e1. DOI: 10.1016/j.cgh.2016.07.016.
[31]	CHENG DY, WAN G, OU WN, et al. Clinical observation of terlivasopressin combined with albumin in the treatment of acute kidney injury in cirrhosis[J]. Chin J Hepatol, 2019, 27(9): 704-707. DOI: 10.3760/cma.j.issn.1007-3418.2019.09.009. 程丹颖, 万钢, 欧蔚妮, 等. 特利加压素联合白蛋白治疗肝硬化急性肾损伤的临床疗效观察[J]. 中华肝脏病杂志, 2019, 27(9): 704-707. DOI: 10.3760/cma.j.issn.1007-3418.2019.09.009.
[32]	LATERRE PF, BERRY SM, BLEMINGS A, et al. Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial[J]. JAMA, 2019, 322(15): 1476-1485. DOI: 10.1001/jama.2019.14607.
[33]	HE X, SU F, TACCONE FS, et al. A Selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock[J]. Crit Care Med, 2016, 44(1): 23-31. DOI: 10.1097/CCM.0000000000001380.
[34]	DEMISELLE J, FAGE N, RADERMACHER P, et al. Vasopressin and its analogues in shock states: a review[J]. Ann Intensive Care, 2020, 10(1): 9. DOI: 10.1186/s13613-020-0628-2.
[35]	WONG F, PANTEA L, SNIDERMAN K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome[J]. Hepatology, 2004, 40(1): 55-64. DOI: 10.1002/hep.20262.
[36]	SKAGEN C, EINSTEIN M, LUCEY MR, et al. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome[J]. J Clin Gastroenterol, 2009, 43(7): 680-685. DOI: 10.1097/MCG.0b013e318188947c.
[37]	FERNÁNDEZ J, MONTEAGUDO J, BARGALLO X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis[J]. Hepatology, 2005, 42(3): 627-634. DOI: 10.1002/hep.20829.
[38]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58(5): 1836-1846. DOI: 10.1002/hep.26338.
[39]	CHEN TA, TSAO YC, CHEN A, et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Scand J Gastroenterol, 2009, 44(5): 619-625. DOI: 10.1080/00365520902719273.
[40]	CHINA L, SKENE SS, BENNETT K, et al. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial[J]. BMJ Open, 2018, 8(10): e023754. DOI: 10.1136/bmjopen-2018-023754.
[41]	SUN L, LIU FY, CHEN XM. Acute kidney disease: raising awareness and improving management of the course[J/CD]. Chin J Kidney Dis Invest(Electronic Edition), 2017, 6(6): 241-245. DOI: 10.3877/cma.j.issn.2095-3216.2017.06.001. 孙林, 刘伏友, 陈香美. 加强对急性肾脏病的认识与管理[J/CD]. 中华肾病研究电子杂志, 2017, 6(6): 241-245. DOI: 10.3877/cma.j.issn.2095-3216.2017.06.001.